Prothena to Participate in Upcoming September Healthcare Conferences
01 Septiembre 2021 - 3:05PM
Prothena to Participate in Upcoming September Healthcare
Conferences
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
company with a robust pipeline of investigational therapeutics
built on protein dysregulation expertise, today announced that
members of its senior management team will participate in the
following September investor conferences:
- Citi’s
16th Annual BioPharma Virtual
Conference on Wednesday, September 8, a fireside chat will
be held at 9:45 AM ET and a panel discussion titled “What’s Next
for Neurodegenerative Diseases” will be held at 11:35 AM ET
- H.C. Wainwright 23rd
Annual Global Investment Conference, on Monday,
September 13, a fireside chat will be available on demand starting
at 7:00 AM ET
- Cantor Global Healthcare Conference on Monday,
September 27, a fireside chat will be held at 11:20 AM ET
A live webcast for all events can be accessed
through the investor relations section of the Company's website
at www.prothena.com. Following the live presentation, a replay
of the webcast will be available on the Company's website for at
least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage
clinical company with a robust pipeline of novel investigational
therapeutics built on protein dysregulation expertise with the
potential to change the course of devastating rare peripheral
amyloid and neurodegenerative diseases. Fueled by its deep
scientific expertise built over decades of research, Prothena is
advancing a pipeline of therapeutic candidates for a number of
indications and novel targets for which its ability to integrate
scientific insights around neurological dysfunction and the biology
of misfolded proteins can be leveraged. Prothena’s pipeline
includes both wholly-owned and partnered programs being developed
for the potential treatment of diseases including AL amyloidosis,
ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a
number of other neurodegenerative diseases. For more information,
please visit the Company’s website at www.prothena.com and follow
the Company on Twitter @ProthenaCorp.
Investors & MediaJennifer Zibuda, Director,
Investor Relations &
Communications650-837-8535, jennifer.zibuda@prothena.com
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
Real-Time news about Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ): 0 recent articles
Más de Artículos de Noticias